Effects of low versus high inspired oxygen fraction on

myocardial injury after transcatheter aortic valve

implantation: A randomized clinical trial

- 5 Youn Joung Cho¹, Cheun Hyeon¹, Karam Nam¹, Seohee Lee¹, Jae-Woo Ju¹, Jeehoon Kang², Jung-
- 6 Kyu Han², Hyo-Soo Kim², Yunseok Jeon^{1*}
- 8 ¹ Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul
- 9 National University College of Medicine, Seoul, South Korea
- ² Department of Internal Medicine, Seoul National University Hospital, Seoul National University
- 11 College of Medicine, Seoul, South Korea
- * Corresponding author

1

2

3

4

7

12

15

17

- 14 E-mail: jeonyunseok@gmail.com
- 16 Short title: oxygen fraction and myocardial injury in transcatheter aortic valve implantation

Abstract

19

20

21

26

33

42

Background

- Oxygen therapy is used in various clinical situation, but its clinical outcomes are inconsistent.
- The relationship between the fraction of inspired oxygen (F_1O_2) during transcatheter aortic
- valve implantation (TAVI) and clinical outcomes has not been well studied. We investigated
- the association of F_1O_2 (low vs. high) and myocardial injury in patients undergoing TAVI.

Methods

- 27 Adults undergoing transfemoral TAVI under general anesthesia were randomly assigned to
- receive F_1O_2 0.3 or 0.8 during procedure. The primary outcome was the area under the curve
- 29 (AUC) for high-sensitivity cardiac troponin I (hs-cTnI) during the first 72 h following TAVI.
- 30 Secondary outcomes included the AUC for postprocedural creatine kinase-myocardial band
- 31 (CK-MB), acute kidney injury and recovery, conduction abnormalities, pacemaker
- implantation, stroke, myocardial infarction, and in-hospital mortality.

Results

- Between October 2017 and April 2022, 72 patients were randomized and 62 were included in
- the final analysis (n=31 per group). The median (IQR) AUC for hs-cTnI in the first 72 h was
- 36 42.66 (24.82–65.44) and 71.96 (35.38–116.34) $h \cdot ng/mL$ in the F_1O_2 0.3 and 0.8 groups,
- 37 respectively (p=0.066). The AUC for CK-MB in the first 72 h was 257.6 (155.6–322.0) and
- 38 342.2 (195.4–485.2) h·ng/mL in the F_1O_2 0.3 and 0.8 groups, respectively (p=0.132). Acute
- kidney recovery, defined as an increase in the estimated glomerular filtration rate $\geq 25\%$ of
- baseline in 48 h, was more common in the F_1O_2 0.3 group (65% vs. 39%, p=0.042). Other
- clinical outcomes were comparable between the groups.

Conclusions

- The F₁O₂ level did not have a significant effect on periprocedural myocardial injury following
- TAVI. However, considering the marginal results, a benefit of low F₁O₂ during TAVI could
- not be ruled out.

49

- 47 **Keywords**: transcatheter aortic valve implantation; intraoperative oxygen; fraction of
- inspired oxygen; oxygen therapy; myocardial injury

Introduction

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Although a fraction of inspired oxygen (F₁O₂) higher than that of ambient air is generally used during general anesthesia, there is continuing debate about the optimal F₁O₂. High oxygen tension is beneficial for reducing surgical site infection and in 2016 World Health Organization recommended that adults receive F_IO₂ 0.8 during mechanical ventilation under general anesthesia [1]. However, a more recent systematic review found no difference in the surgical site infection rate according to the intraoperative F₁O₂ amount, and suggested a negative effect of high F_IO₂ on long-term outcomes [2]. Other investigators did not find any difference in the degree of myocardial injury between perioperative F₁O₂ 0.3 and 0.8, and suggested that F₁O₂ 0.8 is safe for major non-cardiac surgery [3]. High oxygen tension may cause oxidative stress, coronary vasoconstriction, and altered microvascular perfusion, resulting in adverse systemic effects including myocardial injury [4]. In a meta-analysis of acute myocardial infarction (MI), there was no evidence to support the routine use of oxygen treatment and the authors could not rule out a harmful effect of unnecessary oxygen therapy [5]. Constant and brief intermittent hyperoxia both induced inflammatory responses and cytotoxicity in cardiomyocytes from adult humans [6]. Myocardial injury is common following transcatheter aortic valve implantation (TAVI) [7]. Moreover, abnormally increased cardiac biomarkers were associated with poor outcomes including periprocedural kidney injury and 30-day and 1-year mortality following TAVI [8]. The relationship between the F₁O₂ level and myocardial injury has not been well studied in patients undergoing TAVI. Therefore, this study investigated whether high (0.8) and low (0.3) F₁O₂ during transfemoral TAVI under general anesthesia have different effects on post-procedural myocardial injury, as indexed by serum cardiac troponin in the early post-TAVI period.

Methods

76

77

78

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Ethics approval

79 This randomized controlled trial was approved by the Institutional Review Board of Seoul

National University Hospital (#1707-109-871, on September 11, 2017) and registered at

clinicaltrials.gov (NCT03291210, on September 25, 2017) before patient enrollment. The

study was conducted according to the Good Clinical Practice guidelines and Declaration of

Helsinki. Written informed consent was obtained from all participants, who could withdraw

at any time.

Study population and randomization

Adults (aged 20-99 years) with aortic stenosis (AS), undergoing elective TAVI under general

anesthesia via the transfemoral approach in a single tertiary academic center (Seoul National

University Hospital, South Korea), were eligible for the study. Eligibility for TAVI was

based on the consensus of a local multidisciplinary heart team, including clinical

cardiologists, cardiac interventionists, cardiac surgeons, radiologists, and anesthesiologists.

The predicted operative mortality risk was calculated using the Society of Thoracic Surgeons

Predicted Risk of Mortality (STS-PROM) score, European System for Cardiac Operative

Risk Evaluation (EuroSCORE) II, and logistic EuroSCORE. The heart team determined the

anesthetic method (general anesthesia or conscious sedation) based on the patients'

comorbidities, preference, and ability to maintain a supine position without profound dyspnea

or restlessness during the procedure. The exclusion criteria were a non-transfemoral

approach, pre-procedural arterial partial pressure of oxygen (PaO₂) <65 mmHg or receiving

oxygen treatment, severe pre-procedural renal dysfunction (defined as an estimated

glomerular filtration rate [eGFR] <30 mL/min/1.73 m²), chronic pulmonary obstructive disease or symptomatic asthma, tuberculosis-destroyed lung, history of lung cancer, acute coronary syndrome within the past 6 months, documented pre-procedural cardiac troponin I (cTnI) or creatine kinase-myocardial band (CK-MB) elevation, stroke or transient ischemic attack within 6 months, pregnancy, and refusal to participate.

After enrollment and the informed consent process, the patients were randomized to receive F_1O_2 0.3 or 0.8 during TAVI (1:1 allocation ratio) (Fig 1). Block randomization (blocks of four or six) was conducted using a computer-generated program by an independent research nurse on the morning of the intervention. The group assignments were concealed in an opaque envelop, and all investigators, patients, interventionists, and data analyzers were blinded to the group allocations.

Fig 1. CONSORT diagram. CK-MB, creatine kinase-myocardial band; COPD, chronic obstructive pulmonary disease; F₁O₂, fraction of inspired oxygen; PaO₂, arterial partial pressure of oxygen.

Study protocol

The routine monitoring techniques of our institution for patients under general anesthesia were applied, except F₁O₂ management. Without premedication, 12-lead electrocardiogram, pulse oxygen saturation (SpO₂), invasive and noninvasive arterial blood pressure, cerebral oxygen saturation (ScrbO₂), and bispectral index monitoring were performed. Left and right ScrbO₂ were measured using near-infrared spectroscopy (Somanetics INVOS oximeter; Covidien, Mansfield, MA, USA). Transesophageal or transthoracic echocardiography was performed to evaluate the valve position and presence of paravalvular regurgitation, as required by the interventionists.

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

Before inducing anesthesia, all participants were preoxygenated using an anesthesia machine (Primus; Drägerwerk, Lubeck, Germany) with F₁O₂ 0.3 or 0.8 according to the group allocation. After stabilization, general anesthesia was induced by a target-controlled infusion of propofol (effect-site concentration [Ce], 2.5–4.0 µg/mL) and remifentanil (Ce, 1.0–4.0 ng/mL) using a commercial infusion pump (Orchestra, Fresenius Vial, Brézins, France). Neuromuscular blockade was established by administering rocuronium (0.6 mg/kg). Then the trachea was intubated and the lungs were ventilated in volume-controlled mode with a tidal volume of 0.6–0.8 mL/kg and ventilatory rate of 9–12 /min. The alveolar recruitment maneuver was performed at 25 cmH₂O for 10 s after tracheal intubation, and a positive endexpiratory pressure of 5 cmH₂O was applied in all patients. According to the group assignment, F_IO₂ was maintained at 0.3 or 0.8 until the end of the TAVI procedure, unless the SpO₂ was <93%. If desaturation occurred, F₁O₂ was increased by 0.05–0.1, and an additional alveolar recruitment maneuver was performed as needed to maintain SpO₂≥93% by the attending anesthesiologists. On completing the procedure, 100% O₂ was provided to all patients during anesthesia emergence. Patients were extubated in the intervention room. monitored in the cardiovascular care unit for 1–2 days, and then transferred to a general ward. Patients were discharged 5–7 days post-TAVI if they had no procedure-related complications. The TAVI was conducted in accordance with the standard procedures in our institution. Using a transfemoral approach, a balloon-expandable Sapien III valve (Edwards Lifesciences, Irvine, CA, USA), self-expandable Evolut Pro or R valve (Medtronic, Minneapolis, MN, USA), or Lotus valve (Boston Scientific, Natick, MA, USA) was implanted at the diseased aortic valve. The valve was chosen by the heart team based on the size and structure of the native valve and sinus, heights of the coronary artery openings, and considerations regarding future coronary access, the risk of conduction disturbances, and annular calcification. The iliofemoral arteries were accessed under fluoroscopic guidance and

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

closed percutaneously using Perclose ProGlide vascular suture-mediated closure devices (Abbott Vascular Devices, Redwood City, CA, USA). Before the procedure, the patients were given loading doses of dual antiplatelet agents: acetylsalicylic acid and clopidogrel (both 300 mg). During the procedure, the patients were heparinized with unfractionated heparin to achieve an activated clotting time >250 s. At completion of the valve implantation, the effects of heparin were reversed by protamine infusion. During the procedure, arterial blood gas analysis (ABGA) was performed at four time points: baseline (before anesthesia induction, T1), after inducing general anesthesia (T2), after valve implantation (T3), and at the end of the procedure (T4). ABGA was performed using a GEM® Premier 3000 device (Model 5700; Instrumentation Laboratory, Lexington, MA, USA). Two serum cardiac biomarkers of myocardial injury, high-sensitivity cTnI (hs-cTnI) and CK-MB, were measured at baseline (before the procedure) and 1, 4, 8, 24, 48, and 72 h after TAVI. hs-cTnI was measured using an Abbott Architect Plus Analyzer (i2000SR; Flex, San Jose, CA, USA), which has a limit of detection of 0.0011 µg/L and limit of blank of 0.0007–0.0013 µg/L. An hs-cTnI concentration ≥99th percentile in the normal population (0.028 µg/L) was deemed abnormal. Serum creatinine concentrations were calibrated using isotope dilution mass spectrometry (IDMS). The eGFR was calculated using the modified diet in renal disease (MDRD) equation [9]. IDMS MDRD eGFR = $175 \times (\text{serum creatinine})^{-1.154} \times \text{age}^{-0.203} \times (0.742 \text{ for women})$ Postprocedural acute kidney injury (AKI) was determined based on the serum creatinine level and urine output according to the Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines criteria for AKI [10]. AKI was defined as an increase

in serum creatinine ${\ge}1.5$ times the baseline level or by ${\ge}0.3$ mg/dL (${\ge}26.5~\mu mol/L)$

[AKI_{creatinine}], or a urine output <0.5 mL/kg/h for \ge 6 h within 7 days [AKI_{urine output}]. AKI

occurring >7 days after the procedure was excluded because it might have been unrelated to

the procedure. Acute kidney recovery (AKR) was defined as an increase in eGFR of ≥25%

relative to baseline at 48 h post-TAVI [11].

The postprocedural development of new conduction abnormalities and incidence of permanent pacemaker insertion was assessed. Stroke was defined as an acute episode of a focal or global neurological deficit as a result of hemorrhage or infarction, based on the Valve Academic Research Consortium-2 (VARC-2) definition [12]. Periprocedural MI was defined based on a combination of new ischemic symptoms or signs and elevated cardiac biomarkers within 72 h following TAVI, according to the VARC-2 definition [12].

Study endpoints and sample size calculation

The primary study outcome was periprocedural myocardial injury, as reflected by the geometric area under the curve (AUC) for periprocedural serum hs-cTnI in the first 72 h post-TAVI, calculated according to the trapezoidal rule. Secondary outcomes were the AUC for serum CK-MB in the first 72 h post-TAVI, and the peak serum hs-cTnI and CK-MB levels in the same period. Post-procedural clinical outcomes were also evaluated, including AKI, AKR, new conduction abnormalities, permanent pacemaker insertion, stroke, MI, and inhospital cardiovascular mortality.

To calculate the sample size, we conducted a pilot study of 10 patients undergoing transfemoral TAVI under general anesthesia. The AUC for serum hs-cTnI in the first 72 h after TAVI was 40.24 ± 28.16 ng/mL. Assuming that a 50% difference in hs-cTnI levels between the two treatment groups in the first 72 h is clinically relevant, 32 patients were required for each group at 80% power and an alpha error of 5%. Considering a 10% dropout

rate, we recruited 36 patients to each group (a total of 72 patients).

Statistical analysis

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Data are presented as the mean \pm SD, median (interquartile range, IQR), or number (%) after normality was tested using the Kolmogorov–Smirnov test. The primary endpoint, i.e., the AUC for serum hs-cTnI in the first 72 h after TAVI, was analyzed using the Mann–Whitney U test according to the data distribution. Other continuous variables were analyzed using the independent t-test or Mann–Whitney U test after performing a normality test. Categorical variables were analyzed using Pearson's chi square test or Fisher's exact test. For repeated measures, a linear mixed model with Bonferroni correction was used to compare the groups. In the mixed model, group, measurement time, and their interaction were fixed effects, while subject was a random effect. Plots of residuals versus fitted values were checked in terms of whether the error terms (residuals) had a mean of zero and constant variance. The normality assumption for repeated measures was assessed using histograms and quantile-quantile plots (for residuals). Multivariable logistic regression analysis was performed to identify independent risks for F₁O₂ and postprocedural hs-cTnI. Odds ratios (ORs) were adjusted for age, sex, STS-PROM score, C-reactive protein, left ventricular (LV) ejection fraction (EF), procedural time, and new conduction abnormality, and 95% confidence intervals (CIs) were presented. The analysis was done in an intention-to-treat manner. All analyses were performed using IBM SPSS Statistics (ver. 21.0; IBM Corp., Armonk, NY, USA) or R software (ver. 3.5.1; R Development Core Team, Vienna, Austria). A P value <0.05 was considered statistically significant.

Results

Patients were screened for eligibility between October 18, 2017 and April 6, 2022. Of 189 patients, 117 were excluded based on the exclusion criteria (Fig 1). After 72 patients were randomized to the F_1O_2 0.3 or 0.8 groups (n=36 each), 10 patients were excluded due to preprocedural $PaO_2 < 65$ mmHg (n=4), elevated pre-procedural cTnI (n=5), or procedure cancellation (n=1). We noted violations of the exclusion criteria (pre-procedural $PaO_2 < 65$ mmHg or elevated cardiac biomarkers) in nine patients and excluded them from the analysis. Thus, a total of 62 patients (31 per group) were included in the final analysis. We performed additional sub-analysis including five patients (n=2 in the F_1O_2 0.3 group and n=3 in the F_1O_2 0.8 group) who had elevated cardiac biomarkers after randomization.

Tables 1 and 2 present the baseline characteristics of the included patients and procedural variables. Baseline characteristics were well balanced between the groups. The median (IQR) age of the included patients was 79 (77–83) years. The median (IQR) procedural duration was 80 (70–95) min.

Table 1. Baseline characteristics in patients undergoing transfemoral transcatheter aortic valve implantation.

	F ₁ O ₂ 0.3	F _I O ₂ 0.8	p value
	(n=31)	(n=31)	
Demographics			
Age, yr	79 (76–82 [range 64–90])	79 (77–84 [range 58–94])	0.783
Male	12 (39%)	12 (39%)	>0.999
Height, cm	156 ± 10.0	157 ± 10	0.776
Weight, kg	59.1 ± 10.7	60.0 ± 11.0	0.742

Body mass index, kg/m ²	24.29 ± 3.72	24.42 ± 3.69	0.892
Body surface area, m ²	1.58 ± 0.17	1.59 ± 0.18	0.740
Current smoker	1 (3%)	0 (0%)	0.313
NYHA functional class			0.496
I	8 (26%)	6 (19%)	
II	14 (45%)	18 (58%)	
III/IV	9 (29%)	7 (23%)	
Predicted risk calculation			
STS PROM, %	2.759 (1.936–3.724)	3.162 (2.370–4.060)	0.269
EuroSCORE II, %	2.72 (1.64–3.95)	3.54 (1.35–7.01)	0.356
Logistic EuroSCORE, %	4.52 (1.56–7.46)	4.83 (1.95–7.01)	0.564
Echocardiographic and CT data			
LV EF, %	63 (59–67)	66 (61–68)	0.441
AV area, cm ²	0.7 (0.6–0.8)	0.7 (0.6–0.9)	0.309
AV peak velocity, m/s	4.6 ± 0.4	4.6 ± 0.6	0.736
AV mean pressure gradient,	49 (44–60)	50 (43–66)	0.933
mmHg			
AV perimeter, mm	73.0 ± 6.4	72.0 ± 5.6	0.513
LVIDd, mm	46 (42–50)	46 (41–49)	0.534
LVIDs, mm	28 (25–32)	27 (24–31)	0.398
Stroke volume, mL	77 ± 22	81 ± 17	0.538
Height of LMCA os from annulus,	12.7 ± 2.4	12.2 ± 2.2	0.409
mm			
Height of RCA os from annulus,	14.7 ± 2.3	14.2 ± 2.5	0.410
mm			
Baseline laboratory findings			
Hematocrit, %	36.0 ± 4.3	34.8 ± 4.6	0.776
eGFR, ml/min/1.73 m ²	67.5 ± 16.9	66.5 ± 16.0	0.809
Creatinine, mg/dL			

	10 (20 12)	10(25.10)	0.666
Albumin, g/dL	4.0 (3.9–4.3)	4.0 (3.7–4.3)	0.666
hs-cTnI, ng/mL	0.00 (0.00-0.00)	0.00 (0.00-0.00)	0.757
CK-MB, ng/mL	1.1 (1.1–1.4)	1.0 (0.8–1.2)	0.065
hs-CRP, mg/dL	0.07 (0.04–0.33)	0.07 (0.04–0.14)	0.750
Comorbidities			
Hypertension	26 (84%)	22 (71%)	0.224
Diabetes	7 (23%)	11 (36%)	0.263
Dyslipidemia	17 (55%)	21 (68%)	0.297
Coronary artery disease	6 (19%)	7 (23%)	0.755
Angina/previous MI	7 (23%)	6 (19%)	0.755
Medications			
Aspirin	13 (42%)	13 (42%)	>0.999
Anti-platelet agents	12 (39%)	16 (52%)	0.307
Non-vitamin K anticoagulants	3 (10%)	3 (10%)	>0.999
Beta-blockers	19 (61%)	16 (52%)	0.442
ARB/ACEi	20 (65%)	18 (58%)	0.602
Calcium channel blockers	11 (36%)	15 (48%)	0.303
Oral hypoglycemic agents	8 (26%)	9 (29%)	0.776
Diuretics	17 (55%)	14 (45%)	0.446
Nitrates	6 (19%)	4 (13%)	0.490
Statin	19 (61%)	22 (71%)	0.421

241 Values are median (interquartile range), n (%), or mean \pm SD.

242

243

244

245

246

247

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV, aortic valve; CK-MB, creatine kinase-myocardial band; COPD, chronic obstructive pulmonary disease; CT, computed tomography; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; F₁O₂, fraction of inspired oxygen; hs-CRP, high-sensitivity C-reactive protein; hs-cTnI, high-sensitivity cardiac troponin I; LMCA, left main coronary artery; LV, left

ventricular; LVIDd, left ventricular internal diameter end diastole; LVIDs, left ventricular internal diameter end systole; MI, myocardial infarction; NYHA, New York Heart Association; RCA, right coronary artery; STS PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TIA, transient ischemic attack.

248

249

250

251

252

253

254

Table 2. Valve characteristics and procedural variables in patients undergoing transfemoral transcatheter aortic valve implantation.

	$F_1O_2 0.3$	$F_1O_2 0.8$	p value
	(n=31)	(n=31)	
Prosthetic valve type			0.647
Sapien III	13 (42%)	14 (45%)	
Evolut Pro or R	15 (48%)	12 (39%)	
Lotus valve	3 (10%)	5 (16%)	
Prosthetic valve size, mm			0.698
23	6 (19%)	9 (29%)	
25	1 (3%)	2 (7%)	
26	18 (58%)	14 (45%)	
29	6 (19%)	6 (19%)	
Paravalvular regurgitation			0.112
No	12 (39%)	13 (42%)	
Trivial	9 (29%)	15 (48%)	
Mild	9 (29%)	2 (7%)	
Moderate	1 (3%)	1 (3%)	
Procedure duration, min	80 (70–95)	80 (70–95)	0.860
Anesthesia duration, min	140 (120–155)	135 (120–160)	0.888
Amount of contrast media, mL	250 (200–288)	250 (210–326)	0.404

Transfusion of pRBC, unit	0 (0–1)	0 (0–1)	0.675

Values are n (%) or median (interquartile range).

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

F₁O₂, fraction of inspired oxygen; pRBC, packed red blood cell.

During the procedure, PaO₂, arterial oxygen saturation (SaO₂), and SpO₂ were higher in the F₁O₂ 0.8 than F₁O₂ 0.3 group (Fig 2). Two patients in the F₁O₂ 0.3 group required adjustment of F_1O_2 to 0.4 during the procedure because transient $SpO_2 < 93\%$ was observed. The mean left and right cerebral oximetry values were higher in the F_IO₂ 0.8 than F_IO₂ 0.3 group (Fig 2). For serial measurements, interactions between measurement time and group were significant for PaO₂, SaO₂, and the mean ScrbO₂ (p<0.001, <0.001, and 0.032, respectively), but not for SpO_2 (p=0.330).

Fig 2. Changes in arterial oxygenation, pulse oxygen saturation, and cerebral oximetry in patients receiving a fraction of inspired oxygen of 0.3 or 0.8 during transcatheter aortic valve implantation. F₁O₂, fraction of inspired oxygen; PaO₂, arterial partial pressure of oxygen; SaO₂, arterial oxygen saturation; SpO₂, pulse oxygen saturation; ScrbO₂, cerebral oxygen saturation. * p < 0.001 compared to the F_1O_2 0.3 group. # p = 0.003 between the groups (mixed model). § p < 0.05 compared to the F_1O_2 0.3 group.

The primary outcome, the AUC for serum hs-cTnI in the first 72 h post-TAVI, was higher in the F_1O_2 0.8 than F_1O_2 0.3 group (71.96 [35.38–116.34] vs. 42.66 [24.82–65.44] h·ng/mL), but the difference was not statistically significant (p=0.066) (Fig 3). The secondary outcome (AUC for CK-MB in the first 72 h post-TAVI) was also higher in the F_IO₂ 0.8 group, but not significantly (342.2 [195.4–485.2] vs. 257.6 [155.6–322.0] h·ng/mL; p=0.132) (Fig 3). The peak hs-cTnI and CK-MB levels during the first 72 h post-TAVI were also non-

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

significantly higher in the F_1O_2 0.8 group (1.79 [1.09–3.77] vs. 1.30 [1.00–1.58] ng/mL and 10.9 [5.7–15.6] vs. 7.5 [6.0–11.9] ng/mL; p=0.051 and 0.159, respectively). For periprocedural serial measurements, the group differences in hs-cTnI and CK-MB did not reach statistical significance (p=0.125 and 0.084, respectively; mixed model). The interaction between measurement time and group was not significant (p=0.200 and 0.096 for hs-cTnI and CK-MB, respectively). When including the five patients who completed the study protocol and were excluded from the final analysis due to elevated baseline hs-cTnI after randomization, there were no significant differences in the AUCs for hs-cTnI and CK-MB in the first 72 h post-TAVI between the groups (S1 Fig). After adjustment for various risk factors, there was no significant association between the F₁O₂ and AUC for hs-cTnI post-TAVI (OR: 3.644, 95% CI: 0.864–15.371; p=0.078). Fig 3. Changes in cardiac biomarkers in the first 72 h in patients who received a fraction of inspired oxygen of 0.3 or 0.8 during transcatheter aortic valve implantation. AUC, area under the curve; CK-MB, creatine kinase-myocardial band; hs-cTnI, highsensitivity cardiac troponin I; TAVI, transcatheter aortic valve implantation. The postprocedural incidence of AKI did not differ between F_IO₂ 0.3 and 0.8 groups (36% vs. 42%; p=0.602) (Table 3). However, AKR was more frequent in the F_1O_2 0.3 than F_1O_2 0.8 group (65% vs. 39%; p=0.042). Other postprocedural clinical outcomes, such as cardiovascular mortality or length of hospitalization, were comparable between the two groups (Table 3). Table 3. Postprocedural variables in patients received fraction of inspired oxygen 0.3 or 0.8 during transfemoral transcatheter aortic valve implantation.

	F ₁ O ₂ 0.3	F _I O ₂ 0.8	p value
	(n=31)	(n=31)	
Echocardiographic data (at discharge)			
LV EF, %	63 (60–67)	65 (62–69)	0.140
AV area, cm ²	1.8 (1.5–2.1)	1.6 (1.3–1.9)	0.126
AV peak velocity, m/s	2.2 ± 0.4	2.3 ± 0.5	0.350
AV mean pressure gradient, mmHg	10 (6–13)	11 (8–14)	0.386
LVIDd, mm	45 (42–48)	45 (43–47)	0.854
LVIDs, mm	27 (25–31)	27 (25–30)	0.685
Stroke volume, mL	74 ± 24	71 ± 17	0.538
Peak creatinine within 7 days, mg/dL	0.87 (0.77–0.99)	0.89 (0.74–1.16)	0.508
Peak hs-CRP within 72 h, mg/dL	3.71 ± 2.21	4.38 ± 3.23	0.393
	4.14 (1.56–5.22)	4.25 (2.01–5.84)	0.694
AKI within 7 days	11 (36%)	13 (42%)	0.602
AKI _{creatinine}	0 (0%)	3 (10%)	0.238
AKI _{urine output}	11 (36%)	12 (39%)	0.793
AKR within 48 h	20 (65%)	12 (39%)	0.042
Both AKI and AKR	7 (23%)	3 (10%)	0.167
New conduction abnormality	15 (48%)	11 (36%)	0.303
PPM insertion	3 (10%)	4 (13%)	> 0.999
Stroke	1 (3%)	1 (3%)	> 0.999
Myocardial infarction	0	0	
In-hospital mortality	0	0	
Post-procedural hospital length of stay, days	6 (5–7)	5 (5–7)	0.403

Values are median (interquartile range), mean \pm SD, or n (%). AKI was defined as an increase in serum creatinine ≥ 1.5 times the baseline level or by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) for [AKI_{creatinine}], or urine output < 0.5 mL/kg/h for ≥ 6 h within 7 days for [AKI_{urine output}]. AKI, acute kidney injury; AKR, acute kidney recovery; AV, aortic valve; EF, ejection fraction; F_IO₂, fraction of inspired oxygen; LV, left ventricular; LVIDd, left ventricular

304

305

306

307

- internal diameter end diastole; LVIDs, left ventricular internal diameter end systole; PPM, 309
- permanent pacemaker. 310

Discussion

Compared to the F_1O_2 0.3 group, the F_1O_2 0.8 group showed a greater postprocedural elevation of cardiac biomarkers, albeit without statistical significance. Postprocedural AKR was more frequent in the F_1O_2 0.3 group. There was no difference in other periprocedural outcomes between the groups.

Myocardial injury after TAVI

Even after successful TAVI, the cardiac biomarkers cTnI and CK-MB showed post-procedure increases despite prompt relief of transvalvular pressure overload, and periprocedural myocardial injury occurred along with transient deterioration in myocardial function [13]. Significant deterioration in the myocardial performance index, which implies both systolic and diastolic dysfunction, was observed immediately following TAVI [13]. New myocardial late enhancement with an ischemic pattern, indicating myocardial damage, was detected on cardiac magnetic resonance images following both balloon-expandable and self-expandable valve implantation [14].

Transient LV dysfunction and injury following TAVI seems to be partly influenced by procedural aspects of transcatheter valve deployment [15]. Procedure-related mechanical trauma during TAVI, including during balloon valvuloplasty, valve positioning, and prosthesis delivery, also plays a substantial role in myocardial damage [16]. Rapid ventricular pacing is used to temporarily reduce the LV output during pre-implantation balloon valvuloplasty and balloon-expandable valve implantation, and for post-implantation ballooning to reduce paravalvular leakage. Rapid ventricular pacing transiently reduces microvascular tissue perfusion and the flow index in small- and medium-sized vessels, and

induces partial microcirculatory arrest and delayed recovery of microflow [17]. Subsequently, ventricular stunning and subsequent dysfunction may occur [15].

Hyperoxia and myocardial injury

The role of oxidative stress in reperfusion injury is relatively well established. Abrupt oxidative reactions following reperfusion produce reactive oxygen species (ROS) from cardiomyocytes and endothelial cells, which amplifies local inflammatory responses and leads to a vicious cycle of ROS production [18]. The biological mechanism underlying the adverse effects of hyperoxia is related to the generation of ROS, specifically the superoxide anion, which has a negative impact on coronary blood flow and LV distensibility [19]. Hyperoxia can exacerbate oxidative stress and thereby worsen coronary vasoconstriction and myocardial injury. Interestingly, hyperoxic reperfusion limited myocardial necrosis in rodents with cardiovascular risk factors more so than in a normoxemic reperfusion group, while the reverse occurred in healthy rodents [18]. Similarly, in a preliminary canine MI model, administering 100% oxygen had beneficial effects on the myocardium by reducing myocardial infarct size and improving the EF after reperfusion compared to room-air ventilation [20].

However, in the AVOID trial, patients presenting with acute MI were randomized to receive oxygen 8 L/min via face mask or ambient air, and oxygen treatment increased myocardial injury and infarct size in patients without hypoxia [21]. In patients admitted to the intensive care unit (ICU), conservative use of oxygen, which aimed to maintain arterial oxygen tension within the physiological range, reduced ICU mortality compared to conventional use of oxygen [22]. In the large randomized DETO2X-AMI study, there was no difference in 1-year mortality or the peak cardiac troponin level between patients with suspected MI who received supplemental oxygen versus ambient air [23]. During general

anesthesia for major non-cardiac surgery, there was no difference in myocardial injury—assessed using the AUC for high-sensitive troponin in the first 3 postoperative days—between F_1O_2 0.3 and 0.8 administered intraoperatively and for 2 h after surgery [3]. In the ICU-ROX study, conservative use of F_1O_2 (\leq 0.21) during mechanical ventilation in adult ICU patients resulted in no difference in the number of ventilator-free days compared to standard administration of F_1O_2 [24]. In a more recent nationwide registry trial, high oxygen supplementation (6–8 L/min by face mask) resulted in no significant difference in the 30-day or 1-year mortality rate in patients with suspected acute coronary syndrome compared to low oxygen treatment [25].

Myocardial injury and clinical outcomes after TAVI

Cardiac biomarkers elevation following surgery or intervention result from perioperative hemodynamic stress, inflammation, or oxygen supply and demand imbalance [26]. Periprocedural myocardial injury following TAVI was associated with a significantly increased risk of poor short- and long-term clinical outcomes, including 30-day and 1-year mortality, neurological events, and postprocedural permanent pacemaker implantation [27].

In our study, high oxygen tension during TAVI tended to increase the release of cardiac biomarkers in the first 72 h post-TAVI compared to the low oxygen tension group, but the difference was not significant. There was no clinical impact of the level of intraoperative oxygen tension during TAVI, except that recovery of kidney function was more common in the low- compared to the high-F₁O₂ group.

Acute kidney recovery

Acute kidney recovery, which is a relatively recently described phenomenon, has been observed more frequently than AKI after both TAVI and surgical aortic valve replacement

(SAVR) [28]. Following TAVI or SAVR, normalization of the aortic valve area, prompt relief of the trans-aortic pressure gradient, and normalization of post-stenotic flow abnormality occur. Regarding renal blood flow, a rapid increase in cardiac output and reduced LV afterload may cause abrupt hemodynamic changes in the early postprocedural period, such as renal congestion. In a recent prospective registry analysis, both AKI and AKR early after TAVI were independent predictors of cardiovascular mortality [29]. In our study cohort, 10 of the 62 (16%) patients met the criteria for both AKI and AKR during the study period (Table 3). Rapid changes in renal hemodynamics could have occurred in these groups, and both post-TAVI AKI and AKR may reflect a cardiorenal aspect of the extra-cardiac damage characterizing severe AS. Further studies are required to assess the relationship between renal circulatory changes and clinical outcomes in AS patients following TAVI.

Study limitations

This study has some limitations. First, it was a single-center trial with relatively few patients, and was only powered for one surrogate cardiac biomarker, hs-cTnI. Although we observed a trend toward reduced hs-cTnI release and better postprocedural kidney recovery, we cannot definitely conclude that arterial oxygenation is beneficial for patients undergoing TAVI in terms of periprocedural myocardial and renal protection. Second, we included patients undergoing general anesthesia for transfemoral TAVI in this study. However, many patients undergo TAVI under conscious sedation or even local anesthesia, unless they are at very high periprocedural risk due to severely compromised cardiopulmonary function or the inability to maintain a stable supine position, for example. Nevertheless, the included patients had comparable characteristics regarding potential risk factors for postprocedural myocardial injury between the two groups. Future investigators could compare the oxygenation strategies of minimal supplemental oxygen and no supplemental oxygen, as in the treatment of acute

MI patients without hypoxia, in terms of the likelihood of avoiding unnecessary periprocedural oxidative stress and protecting multiple organ systems, in patients undergoing TAVI under conscious sedation or local anesthesia. Third, we included relatively low-risk patients; we excluded those who were already hypoxemic or required supplemental oxygen, and those with acute coronary syndrome or renal failure. In high-risk patients with severe LV dysfunction or poor oxygenation, however, different supplemental oxygen strategies may have a differential impact on myocardial injury and other clinical outcomes. Therefore, further studies are required of high-risk patients, who may be more suitable candidates for TAVI. Lastly, there is lack of control subjects undergoing SAVR in evaluating oxygenation and perioprocedural myocardial injury in this study. As it is beyond the primary aim of the present study, future studies can be conducted regarding periprocedural oxygen content and myocardial injury in patients undergoing TAVI vs. SAVR.

Conclusions

In conclusion, the F_1O_2 level did not have a significant effect on periprocedural myocardial injury following TAVI with general anesthesia. However, considering the marginal results, a benefit of low F_1O_2 during TAVI could not be ruled out.

Acknowledgements

- The authors gratefully acknowledge Sun-Young Jung, a statistician, who is collaborating with
- our institution, for her assistance in the statistical analysis and invaluable advice and
- 432 comments.

429

433

434

References

- 1. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New
- WHO recommendations on intraoperative and postoperative measures for surgical site
- infection prevention: an evidence-based global perspective. Lancet Infect Dis 2016; 16:
- e288–e303. doi: 10.1016/S1473-3099(16)30402-9.
- 439 2. Fasquel C, Huet O, Ozier Y, Quesnel C, Garnier M. Effects of intraoperative high
- versus low inspiratory oxygen fraction (FiO2) on patient's outcome: A systematic
- review of evidence from the last 20 years. Anaesth Crit Care Pain Med 2020; 39: 847–
- 442 858. doi: 10.1016/j.accpm.2020.07.019.
- Holse C, Aasvang EK, Vester-Andersen M, Rasmussen LS, Wetterslev J, Christensen
- R, et al. Hyperoxia and Antioxidants for Myocardial Injury in Noncardiac Surgery: A 2
- 445 x 2 Factorial, Blinded, Randomized Clinical Trial. Anesthesiology 2022; 136: 408-419.
- doi: 10.1097/ALN.0000000000004117.
- 4. Damiani E, Donati A, Girardis M. Oxygen in the critically ill: friend or foe? Curr Opin
- Anaesthesiol 2018; 31: 129–135. doi: 10.1097/ACO.000000000000559.
- 5. Cabello JB, Burls A, Emparanza JI, Bayliss SE, Quinn T. Oxygen therapy for acute
- myocardial infarction. Cochrane Database Syst Rev 2016; 12: CD007160. doi:
- 451 10.1002/14651858.CD007160.pub4.
- 452 6. Hafner C, Wu J, Tiboldi A, Hess M, Mitulovic G, Kaun C, et al. Hyperoxia Induces

- Inflammation and Cytotoxicity in Human Adult Cardiac Myocytes. Shock 2017; 47: 453
- 436-444. doi: 10.1097/SHK.0000000000000740. 454
- Carrabba N, Valenti R, Migliorini A, Vergara R, Parodi G, Antoniucci D. Prognostic 455 7.
- value of myocardial injury following transcatheter aortic valve implantation. Am J 456
- Cardiol 2013; 111: 1475–1481. doi: 10.1016/j.amjcard.2013.01.301. 457
- 8. Barbash IM, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R, et al. Prevalence and 458
- effect of myocardial injury after transcatheter aortic valve replacement. Am J Cardiol 459
- 2013; 111: 1337–1343. doi: 10.1016/j.amjcard.2012.12.059. 460
- 461 9. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using
- standardized serum creatinine values in the modification of diet in renal disease study 462
- equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254. 463
- doi: 10.7326/0003-4819-145-4-200608150-00004. 464
- Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin 10. 465
- Pract 2012; 120: c179–184. doi: 10.1159/000339789. 466
- 11. Azarbal A, Malenka DJ, Huang YL, Ross CS, Solomon RJ, DeVries JT, et al. Recovery 467
- of Kidney Dysfunction After Transcatheter Aortic Valve Implantation (from the 468
- Northern New England Cardiovascular Disease Study Group). Am J Cardiol 2019; 123: 469
- 426–433. doi: 10.1016/j.amjcard.2018.10.042. 470
- Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et 12. 471
- al. Updated standardized endpoint definitions for transcatheter aortic valve 472
- implantation: the Valve Academic Research Consortium-2 consensus document. Eur 473
- Heart J 2012; 33: 2403–2418. doi: 10.1093/eurheartj/ehs255. 474
- 13. Dworakowski R, Wendler O, Bhan A, Smith L, Pearson P, Alcock E, et al. Successful 475
- transcatheter aortic valve implantation (TAVI) is associated with transient left 476
- ventricular dysfunction. Heart 2012; 98: 1641–1646. doi: 10.1136/heartjnl-2012-477

- 302505. 478
- Kim WK, Rolf A, Liebetrau C, Van Linden A, Blumenstein J, Kempfert J, et al. 479
- Detection of myocardial injury by CMR after transcatheter aortic valve replacement. J 480
- Am Coll Cardiol 2014; 64: 349–357. doi: 10.1016/j.jacc.2014.03.052. 481
- Sarraf M, Burkhoff D, Brener MI. First-in-Man 4-Chamber Pressure-Volume Analysis 482 15.
- During Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Disease. 483
- JACC Case Rep 2021; 3: 77–81. doi: 10.1016/j.jaccas.2020.11.041. 484
- 16. Kim WK, Liebetrau C, van Linden A, Blumenstein J, Gaede L, Hamm CW, et al. 485
- 486 Myocardial injury associated with transcatheter aortic valve implantation (TAVI). Clin
- Res Cardiol 2016; 105: 379–387. doi: 10.1007/s00392-015-0949-6. 487
- 17. Selle A, Figulla HR, Ferrari M, Rademacher W, Goebel B, Hamadanchi A, et al. 488
- Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion. Clin 489
- Res Cardiol 2014; 103: 902–911. doi: 10.1007/s00392-014-0728-9. 490
- Acheampong A, Melot C, Benjelloun M, Cheval M, Reye F, Delporte C, et al. Effects 491 18.
- of hyperoxia and cardiovascular risk factors on myocardial ischaemia-reperfusion 492
- injury: a randomized, sham-controlled parallel study. Exp Physiol 2021; 106: 1249-493
- 1262. doi: 10.1113/EP089320. 494
- Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular 19. 495
- function and filling pressures in patients with and without congestive heart failure. 496
- Chest 2001; 120: 467–473. doi: 10.1378/chest.120.2.467. 497
- Kelly RF, Hursey TL, Parrillo JE, Schaer GL. Effect of 100% oxygen administration on 20. 498
- infarct size and left ventricular function in a canine model of myocardial infarction and 499
- reperfusion. Am Heart J 1995; 130: 957–965. doi: 10.1016/0002-8703(95)90194-9. 500
- Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air Versus 21. 501
- Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation 2015; 131: 2143-502

- 2150. doi: 10.1161/CIRCULATIONAHA.114.014494. 503
- 22. Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of 504
- Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an 505
- Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. JAMA 2016; 316: 506
- 1583–1589. doi: 10.1001/jama.2016.11993. 507
- Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen 508 23.
- 509 Therapy in Suspected Acute Myocardial Infarction. N Engl J Med 2017; 377: 1240–
- 1249. doi: 10.1056/NEJMoa1706222. 510
- 511 24. ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society
- Clinical Trials Group, Mackle D, Bellomo R, Bailey M, Beasley R, Deane A, et al. 512
- Conservative Oxygen Therapy during Mechanical Ventilation in the ICU. N Engl J 513
- Med 2020; 382: 989-998. doi: 10.1056/NEJMoa1903297. 514
- 25. Stewart RAH, Jones P, Dicker B, Jiang Y, Smith T, Swain A, et al. High flow oxygen 515
- and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, 516
- cluster randomised, crossover trial. BMJ 2021; 372: n355. doi: 10.1136/bmj.n355. 517
- Buse GL, Matot I. Pro-Con Debate: Cardiac Troponin Measurement as Part of Routine 26. 518
- Follow-up of Myocardial Damage Following Noncardiac Surgery. Anesth Analg 2022; 519
- 134: 257-265. doi: 10.1213/ANE.000000000005714. 520
- 27. Michail M, Cameron JN, Nerlekar N, Ihdayhid AR, McCormick LM, Gooley R, et al. 521
- Periprocedural Myocardial Injury Predicts Short- and Long-Term Mortality in Patients 522
- Undergoing Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv 2018; 11: 523
- e007106. doi: 10.1161/CIRCINTERVENTIONS.118.007106. 524
- 28. Lahoud R, Butzel DW, Parsee A, Huang YL, Solomon RJ, DeVries JT, et al. Acute 525
- Kidney Recovery in Patients Who Underwent Transcatheter Versus Surgical Aortic 526
- Valve Replacement (from the Northern New England Cardiovascular Disease Study 527

Group). Am J Cardiol 2020; 125: 788–794. doi: 10.1016/j.amjcard.2019.11.024. 528 Peillex M, Marchandot B, Matsushita K, Prinz E, Hess S, Reydel A, et al. Acute kidney 529 injury and acute kidney recovery following Transcatheter Aortic Valve Replacement. 530 PLoS One 2021; 16: e0255806. doi: 10.1371/journal.pone.0255806. 531 532 **Supporting information** 533 S1 Fig. Changes in cardiac biomarkers in the first 72 h in patients including five 534 patients who were excluded from the main analysis due to pre-procedural elevation of 535 cardiac biomarkers after randomization and received a fraction of inspired oxygen of 536 0.3 or 0.8 during transcatheter aortic valve implantation. AUC, area under the curve; CK-537 MB, creatine kinase-myocardial band; hs-cTnI, high sensitivity cardiac troponin I; TAVI, 538 transcatheter aortic valve implantation. 539 S1 CONSORT Checklist. 540 541 Financial disclosure statement 542 The authors received no specific funding for this work. 543




Figure1




Figure2




Figure3